Developer docs
API playgroundTry for free, no card

Search company profiles

sanofi kk

Full company profile

uuid02mfjx5

Namestring
sanofi kk
Legal namestring
サノフィ株式会社
Websiteurl
sanofi.co.jp
Company typeenum
Private
Founded yearstring
-
Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
51–100
akta.pro rankint
HeadquartersTokyo, Japan
HQ citystring
Tokyo
HQ countrystring
Japan
HQ regionstring
Asia
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
prescription pharmaceuticals, vaccines and biologics, rare disease therapies, diabetes treatment, biopharmaceutical manufacturing
Industry4 codes
PRIMARYHLAAAAAB
Recombinant Protein Therapeutics (enzymes, hormones, growth factors)
Healthcare & Life Sciences/Biotechnology & Biologics/Therapeutic Biologics (mAbs, recombinant proteins, cytokines)
SECONDARYHLAIACAD
Endocrinology & Metabolic Specialty Pharmaceuticals
SECONDARYHLAJAHAM
Consent, Documentation & Certification (Records/Passports/Proof of Vaccination)
Healthcare & Life Sciences/Public Health, Government & Regulators/Immunization Programs & Vaccine Administration
SECONDARYEDAHAGAJ
Health Informatics & Digital Health Programs
Education/Higher Education (Colleges & Universities)/Medical & Health Sciences Universities
NAICS code2 codes
  • Pharmaceutical Preparation Manufacturing325412
  • Pharmaceutical and Medicine Manufacturing3254
SIC code1 code
  • Pharmaceutical Preparations2834
Product category
Pharmaceuticals
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model3 records
1Prescription Pharmaceuticals
TypeOne Time License
Description

Sale of prescription drugs across multiple therapeutic areas including immunology, neurology, oncology, rare blood disorders, rare diseases, diabetes, and cardiovascular disease

sanofi.co.jp
2Vaccines
TypeOne Time License
Description

Development and sale of vaccines including yellow fever vaccine

sanofi.co.jp
3Generic and Biosimilar Products
TypeOne Time License
Description

Sale of generic versions of insulin products and bio-similar products

sanofi.co.jp
Marketing channels7 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels2 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Technology or R&D, Supply Chain, Personnel, Marketing or Sales, Operations
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 of 5 records shown
1SoloSmart®
Description

Digital health application for diabetes patients using smart insulin pens; compatible software application that helps patients track insulin dosing, blood glucose, and other diabetes management data

sanofi.co.jp
+4 more records
Core offering1 text field

Sanofi K.K. is the Japanese operating subsidiary of global biopharmaceutical company Sanofi S.A., headquartered in Tokyo. The company develops, manufactures, and commercializes prescription medicines, vaccines, and biosimilars across therapeutic areas including immunology, neurology, oncology, rare blood disorders, rare diseases, diabetes, and cardiovascular disease. It also markets a digital health companion app and a medical device for insulin delivery.

Differentiator
Functional benefit
Problem solved
Product overview1 text field

Sanofi KK is a research and development-driven, AI-powered global biopharmaceutical company operating in Japan. The company's product portfolio spans multiple therapeutic areas including immunology, oncology, neurology, rare blood disorders, rare diseases, diabetes, and cardiovascular diseases. Key products include insulin analogs (Apidra, Lantus) and biosimilar insulins delivered via SoloStar pen devices, specialty pharmaceuticals like Dupixent and Sarclisa, vaccines including Menquadfi and Yellow Fever Vaccine, and the SoloSmart connected smart insulin pen system. The company also operates patient support initiatives such as the MMoving Forward global multiple myeloma program and maintains environmental sustainability commitments through its Planet Mobilization strategy.

Product and service5 records
1Lantus SoloStar
CategoryDiabetes / Insulins
2Apidra SoloStar
CategoryDiabetes / Insulins
3Dupixent (dupilumab)
CategoryImmunology / Dermatology & Respiratory
4Sarclisa (isatuximab)
CategoryOncology / Hematology
5Elplat (oxaliplatin)
Scale indicator3 records

Each record includes

Type, Value, Description, Source

Partnership6 partners
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2025-03-24
Description

Global initiative bringing together multiple myeloma experts, patient advocacy groups, and healthcare professionals to improve patient outcomes and quality of life. Alliance includes International Myeloma Foundation, Myeloma UK, Myeloma Patients Europe, and various academic and clinical experts worldwide.

2International Myeloma Foundation
Strategic tierCoreTypeStrategic or Co-development Partner
Description

Represented by Yelak Biru (President), part of the MMoving Forward Alliance focusing on patient unmet needs and quality of life improvements

sanofi.co.jp
3Myeloma UK
Strategic tierCoreTypeStrategic or Co-development Partner
Description

Represented by Sophie Castell (CEO), contributing to shared decision-making and patient engagement initiatives

sanofi.co.jp
4Myeloma Patients Europe
Strategic tierCoreTypeStrategic or Co-development Partner
Description

Represented by Katie Joyner (Co-CEO) and Diane Loening-Martens (Vice President), supporting patient-centered care and quality of life improvements

sanofi.co.jp
5くすりの適正使用協議会 (RAD-AR)
Strategic tierMinorTypeStrategic or Co-development Partner
Description

Partnership for patient education on proper medication usage and safety information

sanofi.co.jp
6European Oncology Nursing Society (EONS)
Strategic tierMinorTypeStrategic or Co-development Partner
Description

Nursing society contributing to patient care journey improvements in multiple myeloma through nursing role development

sanofi.co.jp
Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Japanese subsidiary of a global pharma; directly competes with Sanofi in vaccines, oncology, immunology, and diabetes via the same MR-to-pharmacy/hospital distribution.

2Chugai Pharmaceutical
TypeDirect peer
Description

Roche-affiliated Japanese pharma leader with biologics and specialty therapeutics in immunology and oncology; directly comparable as a multinational-pharma Japanese subsidiary competing in Sanofi's core franchises.

TypeDirect peer
Description

Japanese operating arm of a global pharma; serves the same hospital, specialty, and rare-disease channels with overlapping cardiovascular, neurology, and immunology product lines.

TypeDirect peer
Description

Largest Japanese-headquartered global pharma; competes with Sanofi K.K. across immunology, rare diseases, oncology, neurology, and diabetes in the Japan market with overlapping HCP and patient segments.

TypeDirect peer
Description

Japanese pharma arm of a global life sciences group; competes in cardiovascular, oncology, women's health, and imaging products through overlapping hospital and pharmacy channels.

TypeDirect peer
Description

Top-tier Japanese pharma with oncology and specialty franchises; competes with Sanofi in oncology and rare disease products distributed through the same hospital and pharmacy channels.

7AstraZeneca Japan
TypeDirect peer
Description

Japanese subsidiary of a global biopharma; overlaps Sanofi in oncology, cardiovascular, respiratory, and rare disease categories sold to the same Japanese HCPs.

TypeDirect peer
Description

Japanese subsidiary of a global pharma; competes in oncology, immunology, and diagnostics-adjacent digital health offerings parallel to Sanofi's portfolio strategy.

TypeDirect peer
Description

Major Japanese pharma with oncology, immunology, and neurology franchises that overlap Sanofi's therapeutic areas in the same Japanese commercial channels.

TypeDirect peer
Description

Japanese subsidiary of a global biopharma; competes head-to-head with Sanofi K.K. across vaccines, oncology, immunology, and rare diseases served through the same MR-led channel model.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers2 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment2 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile1 record

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature2 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles1 record

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

Subsidiaries3 records

Each record includes

Name, Acquired on, Relationship type, Type, Business focus

No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

sanofi kk

Pharmaceuticalssanofi.co.jp

sanofi kk firmographics

Firmographics
Name
sanofi kk
Legal name
サノフィ株式会社
Website
https://sanofi.co.jp
Company type
Private
Operating status
Operating
Headcount range
51–100 employees
Ownership category
akta.pro rank

sanofi kk industry classification

Industry
Product category
Pharmaceuticals
NAICS
Pharmaceutical Preparation Manufacturing (325412), Pharmaceutical and Medicine Manufacturing (3254)
SIC
Pharmaceutical Preparations (2834)
akta.pro industry
PRIMARYHLAAAAAB
Recombinant Protein Therapeutics (enzymes, hormones, growth factors)
Healthcare & Life Sciences/Biotechnology & Biologics/Therapeutic Biologics (mAbs, recombinant proteins, cytokines)
SECONDARYHLAIACAD
Endocrinology & Metabolic Specialty Pharmaceuticals
SECONDARYHLAJAHAM
Consent, Documentation & Certification (Records/Passports/Proof of Vaccination)
Healthcare & Life Sciences/Public Health, Government & Regulators/Immunization Programs & Vaccine Administration
SECONDARYEDAHAGAJ
Health Informatics & Digital Health Programs
Education/Higher Education (Colleges & Universities)/Medical & Health Sciences Universities

Keywords

  • Prescription pharmaceuticals
  • Vaccines and biologics
  • Rare disease therapies
  • Diabetes treatment
  • Biopharmaceutical manufacturing

Where sanofi kk is headquartered

Location

Headquarters

HQ city
Tokyo
HQ country
Japan
HQ region
Asia

Offices1 record

Markets served

sanofi kk business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Supply Chain, Personnel, Marketing or Sales, Operations

Revenue model

  1. Prescription Pharmaceuticals: Sale of prescription drugs across multiple therapeutic areas including immunology, neurology, oncology, rare blood disorders, rare diseases, diabetes, and cardiovascular disease
  2. Vaccines: Development and sale of vaccines including yellow fever vaccine
  3. Generic and Biosimilar Products: Sale of generic versions of insulin products and bio-similar products

Go-to-market motion1 record

Distribution channels2 records

Marketing channels7 records

sanofi kk product offering

Product offering

Core offering

Sanofi K.K. is the Japanese operating subsidiary of global biopharmaceutical company Sanofi S.A., headquartered in Tokyo. The company develops, manufactures, and commercializes prescription medicines, vaccines, and biosimilars across therapeutic areas including immunology, neurology, oncology, rare blood disorders, rare diseases, diabetes, and cardiovascular disease. It also markets a digital health companion app and a medical device for insulin delivery.

Product overview

Sanofi KK is a research and development-driven, AI-powered global biopharmaceutical company operating in Japan. The company's product portfolio spans multiple therapeutic areas including immunology, oncology, neurology, rare blood disorders, rare diseases, diabetes, and cardiovascular diseases. Key products include insulin analogs (Apidra, Lantus) and biosimilar insulins delivered via SoloStar pen devices, specialty pharmaceuticals like Dupixent and Sarclisa, vaccines including Menquadfi and Yellow Fever Vaccine, and the SoloSmart connected smart insulin pen system. The company also operates patient support initiatives such as the MMoving Forward global multiple myeloma program and maintains environmental sustainability commitments through its Planet Mobilization strategy.

Differentiator

Problem solved

Functional benefit

Brands

  • SoloSmart®: Digital health application for diabetes patients using smart insulin pens; compatible software application that helps patients track insulin dosing, blood glucose, and other diabetes management data
  • DM-TOWN
  • MMoving Forward
  • La Maison Business Support Center (LMBC)
  • Chasing Miracles

Products and services

  • Lantus SoloStar
  • Apidra SoloStar
  • Dupixent (dupilumab)
  • Sarclisa (isatuximab)
  • Elplat (oxaliplatin)

Companies that use sanofi kk

Customer profile

Named customers2 records

Segments2 records

Ideal customer profiles1 record

sanofi kk technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature2 records

sanofi kk partnerships and signals

Strategic signal

Partnerships

Six partnerships are on record, tiered core and minor.

  • MMoving Forward AlliancecoreStrategic or Co-development Partner · 24 March 2025Global initiative bringing together multiple myeloma experts, patient advocacy groups, and healthcare professionals to improve patient outcomes and quality of life. Alliance includes International Myeloma Foundation, Myeloma UK, Myeloma Patients Europe, and various academic and clinical experts worldwide.
  • International Myeloma FoundationcoreStrategic or Co-development PartnerRepresented by Yelak Biru (President), part of the MMoving Forward Alliance focusing on patient unmet needs and quality of life improvements
  • Myeloma UKcoreStrategic or Co-development PartnerRepresented by Sophie Castell (CEO), contributing to shared decision-making and patient engagement initiatives
  • Myeloma Patients EuropecoreStrategic or Co-development PartnerRepresented by Katie Joyner (Co-CEO) and Diane Loening-Martens (Vice President), supporting patient-centered care and quality of life improvements
  • くすりの適正使用協議会 (RAD-AR)minorStrategic or Co-development PartnerPartnership for patient education on proper medication usage and safety information
  • European Oncology Nursing Society (EONS)minorStrategic or Co-development PartnerNursing society contributing to patient care journey improvements in multiple myeloma through nursing role development

Scale indicators3 records

Recent moves6 records

Expansion highlights5 records

sanofi kk competitors and assessment

Company assessment

Direct peers

  • MSD Japan (Merck): Japanese subsidiary of a global pharma; directly competes with Sanofi in vaccines, oncology, immunology, and diabetes via the same MR-to-pharmacy/hospital distribution.
  • Chugai Pharmaceutical: Roche-affiliated Japanese pharma leader with biologics and specialty therapeutics in immunology and oncology; directly comparable as a multinational-pharma Japanese subsidiary competing in Sanofi's core franchises.
  • Novartis Pharma Japan: Japanese operating arm of a global pharma; serves the same hospital, specialty, and rare-disease channels with overlapping cardiovascular, neurology, and immunology product lines.
  • Takeda Pharmaceutical: Largest Japanese-headquartered global pharma; competes with Sanofi K.K. across immunology, rare diseases, oncology, neurology, and diabetes in the Japan market with overlapping HCP and patient segments.
  • Bayer Yakuhin: Japanese pharma arm of a global life sciences group; competes in cardiovascular, oncology, women's health, and imaging products through overlapping hospital and pharmacy channels.
  • Daiichi Sankyo: Top-tier Japanese pharma with oncology and specialty franchises; competes with Sanofi in oncology and rare disease products distributed through the same hospital and pharmacy channels.
  • AstraZeneca Japan: Japanese subsidiary of a global biopharma; overlaps Sanofi in oncology, cardiovascular, respiratory, and rare disease categories sold to the same Japanese HCPs.
  • Roche Japan: Japanese subsidiary of a global pharma; competes in oncology, immunology, and diagnostics-adjacent digital health offerings parallel to Sanofi's portfolio strategy.
  • Astellas Pharma: Major Japanese pharma with oncology, immunology, and neurology franchises that overlap Sanofi's therapeutic areas in the same Japanese commercial channels.
  • Pfizer Japan: Japanese subsidiary of a global biopharma; competes head-to-head with Sanofi K.K. across vaccines, oncology, immunology, and rare diseases served through the same MR-led channel model.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

sanofi kk social profiles

Digital presence

sanofi kk financial estimates

Financial estimate

Revenue estimate

Valuation estimate

sanofi kk leadership team

Management profile

Number of profiles

Profiles1 record

sanofi kk subsidiaries and ownership

Company hierarchy

Subsidiaries3 records

sanofi kk funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

sanofi kk M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about sanofi kk

What does sanofi kk do?

Sanofi K.K. is the Japanese operating subsidiary of global biopharmaceutical company Sanofi S.A., headquartered in Tokyo. The company develops, manufactures, and commercializes prescription medicines, vaccines, and biosimilars across therapeutic areas including immunology, neurology, oncology, rare blood disorders, rare diseases, diabetes, and cardiovascular disease. It also markets a digital health companion app and a medical device for insulin delivery.

Is sanofi kk a public or private company?

sanofi kk is a private company. It is classified as corporate owned and is currently operating.

When was sanofi kk founded?

sanofi kk was founded in -1. It employs 51 to 100 people.

Where is sanofi kk based?

sanofi kk is headquartered in Tokyo, Japan, in the Asia region.

How does sanofi kk make money?

Three revenue lines are on record. Prescription Pharmaceuticals are the primary driver. The others are vaccines and generic and Biosimilar Products.

Who are sanofi kk's main competitors?

Direct peers on record are MSD Japan (Merck), Chugai Pharmaceutical, Novartis Pharma Japan, Takeda Pharmaceutical, Bayer Yakuhin, Daiichi Sankyo, AstraZeneca Japan, Roche Japan, Astellas Pharma and Pfizer Japan.

Does sanofi kk have an API?

No public API is recorded for sanofi kk.

What industry is sanofi kk in?

sanofi kk's product category is Pharmaceuticals. Its primary akta.pro industry code is HLAAAAAB, Recombinant Protein Therapeutics (enzymes, hormones, growth factors), with a secondary code of HLAIACAD, Endocrinology & Metabolic Specialty Pharmaceuticals. Its NAICS code is 325412 and its SIC code is 2834.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales